Literature DB >> 15814630

Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.

Nobuhiro Nitori1, Yoshinori Ino, Yukihiro Nakanishi, Tesshi Yamada, Kazufumi Honda, Kazuyoshi Yanagihara, Tomoo Kosuge, Yae Kanai, Masaki Kitajima, Setsuo Hirohashi.   

Abstract

Tissue factor (TF) is a transmembrane glycoprotein that plays roles in the blood coagulation and intracellular signaling pathways, and has also been suggested to modulate the biological behavior of cancer cells. In order to examine the clinicopathologic significance of TF expression in pancreatic ductal adenocarcinoma, TF expression was determined by immunohistochemistry using a newly raised anti-TF monoclonal antibody in 113 patients who had undergone surgical resection of pancreatic ductal adenocarcinoma. According to the incidence of tumor cell immunopositivity, patients were divided into "negative TF" (0%), "weak TF" (<25%), or "high TF" (25% or more) groups, which accounted for 11.6% (n = 13), 44.2% (n = 50), and 44.2% (n = 50) of the total, respectively. Increased TF expression was correlated with the extent of the primary tumor (P = 0.0043), lymph node metastasis (P = 0.0043), lymphatic distant metastasis (P = 0.0039), advanced tumor-node-metastasis stage (P = 0.0002), and high tumor grade (P = 0.0164). Multivariate analysis using the Cox proportional hazards model showed that high TF expression was an independent negative predictor for survival (hazard ratio, 2.014; P = 0.0076). Moreover, patients with TF-negative tumors had a significantly better prognosis even if lymph node metastasis was present (P < 0.0001). We also showed that TF knockdown by RNA interference suppressed the invasiveness of a pancreatic adenocarcinoma cell line in vitro. These results indicate that TF expression may contribute to the aggressiveness of pancreatic ductal adenocarcinoma by stimulating tumor invasiveness, and that evaluation of the primary tumor for TF expression may identify patients with a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814630     DOI: 10.1158/1078-0432.CCR-04-0866

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  RNA interference characterization of proteins discovered by proteomic analysis of pancreatic cancer reveals function in cell growth and survival.

Authors:  Candy N Lee; Jenny L Heidbrink; Katherine McKinnon; Victoria Bushman; Henrik Olsen; William FitzHugh; Aiqun Li; Karen Van Orden; Tao He; Steven M Ruben; Paul A Moore
Journal:  Pancreas       Date:  2012-01       Impact factor: 3.327

2.  Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma.

Authors:  Andreia Da Silva de Oliveira; Luize G Lima; Andréa Mariano-Oliveira; Daniel E Machado; Luiz E Nasciutti; John F Andersen; Lars C Petersen; Ivo M B Francischetti; Robson Q Monteiro
Journal:  Thromb Res       Date:  2012-06-09       Impact factor: 3.944

3.  Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation.

Authors:  Stephan L Haas; Ralf Jesnowski; Michael Steiner; Frank Hummel; Jörg Ringel; Christine Burstein; Horst Nizze; Stefan Liebe; J Matthias Löhr
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

4.  ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836.

Authors:  Reinier Hernandez; Christopher G England; Yunan Yang; Hector F Valdovinos; Bai Liu; Hing C Wong; Todd E Barnhart; Weibo Cai
Journal:  J Control Release       Date:  2017-08-24       Impact factor: 9.776

5.  Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.

Authors:  Yi Yang; Amanda Stang; Patrick G Schweickert; Nadia A Lanman; Erin N Paul; Brett P Monia; Alexey S Revenko; Joseph S Palumbo; Eric S Mullins; Bennett D Elzey; Edith M Janssen; Stephen F Konieczny; Matthew J Flick
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

Review 6.  Pathophysiology and management of thrombosis in cancer: 150 years of progress.

Authors:  Gerald A Soff
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 7.  Venous thromboembolism and prognosis in cancer.

Authors:  Alok A Khorana
Journal:  Thromb Res       Date:  2010-01-25       Impact factor: 3.944

8.  Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer.

Authors:  A A Khorana; C W Francis; K E Menzies; J-G Wang; O Hyrien; J Hathcock; N Mackman; M B Taubman
Journal:  J Thromb Haemost       Date:  2008-09-15       Impact factor: 5.824

9.  Immuno-PET of tissue factor in pancreatic cancer.

Authors:  Hao Hong; Yin Zhang; Tapas R Nayak; Jonathan W Engle; Hing C Wong; Bai Liu; Todd E Barnhart; Weibo Cai
Journal:  J Nucl Med       Date:  2012-09-17       Impact factor: 10.057

10.  Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer.

Authors:  Haiming Luo; Christopher G England; Sixiang Shi; Stephen A Graves; Reinier Hernandez; Bai Liu; Charles P Theuer; Hing C Wong; Robert J Nickles; Weibo Cai
Journal:  Clin Cancer Res       Date:  2016-03-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.